University of Arizona
2 papers in the library · 795 citations · publishing 2006-2025
The Journal of Clinical Psychiatry November 15, 2006 Francisco Moreno, Christopher B. Wiegand, E. Keolani Taitano et al. 786 citations
In a controlled clinical setting, psilocybin was safely administered to individuals with obsessive-compulsive disorder (OCD) and was linked to immediate decreases in core OCD symptoms in several participants.
Psychedelic Medicine January 20, 2025 Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano et al. 9 citations
Psilocybin and other serotonergic psychedelics are used in research settings with safety measures including controlled environments, staff presence, screening, and psychoeducation. An analysis of study materials from psilocybin trials over the past two decades found that psychoeducation documents varied but commonly emphasized biological and physical safety, psychological safety and well-being, aspects of setting, and the potential for expectancies. The materials prioritized biological and psychological safety across all sites. The authors also identified elements unrelated to safety that may contribute to participant expectancies and suggest these extrapharmacological factors be studied systematically to maximize safety while minimizing extraneous expectancies.